Ethanamine, 2,2,2-trifluoro- → HCID 59592893, compound

HRID 2098634Notes

Reaction equation

HRID 2098634 reaction equation
[NH:1]1[C:9]2[C:4](=[C:5]([C:10]3[N:11]=[C:12]([N:22]4[CH2:27][CH2:26][O:25][CH2:24][CH2:23]4)[C:13]4[CH:18]=[C:17]([C:19]([OH:21])=O)[S:16][C:14]=4[N:15]=3)[CH:6]=[CH:7][CH:8]=2)[CH:3]=[N:2]1.[F:28][C:29]([F:33])([F:32])[CH2:30][NH2:31]>>[F:28][C:29]([F:33])([F:32])[CH2:30][NH:31][C:19]([C:17]1[S:16][C:14]2[N:15]=[C:10]([C:5]3[CH:6]=[CH:7][CH:8]=[C:9]4[C:4]=3[CH:3]=[N:2][NH:1]4)[N:11]=[C:12]([N:22]3[CH2:23][CH2:24][O:25][CH2:26][CH2:27]3)[C:13]=2[CH:18]=1)=[O:21]

Participants

3

Reactant 2

HCID 9773Ethanamine, 2,2,2-trifluoro-HCID 595928852-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidine-6-carboxylic acid

Product 1

HCID 59592893HCID 59592893, compound

Procedure

45 mg of 2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidine-6-carboxylic acid 14 was coupled to 2,2,2-trifluoroethanamine via General Procedure B. The product was purified via reverse phase HPLC to give 15 mg of 127. MS (Q1) 463.1 (M)+.

Workup

  1. customThe product was purified via reverse phase HPLC

Sources & evidence

ORD record
ord-a39b8cab626841cf9d9f32707b99f50d
Source dataset
uspto-grants-2013_05
Patent number
US08450315B2

Reaction notes

Loading…